Palbociclib and cetuximab in platinum-resistant and in cetuximab-resistant human papillomavirus-unrelated head and neck cancer: a multicentre, multigroup, phase 2 trialDouglas R. Adkins, Peter Oppelt, Assuntina G. Sacco et al.|The Lancet Oncology|2019Cited by 125
Pazopanib plus cetuximab in recurrent or metastatic head and neck squamous cell carcinoma: an open-label, phase 1b and expansion studyDouglas R. Adkins, Peter Oppelt, Paul Mehan et al.|The Lancet Oncology|2018Cited by 27